Human Growth Hormone Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Product, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global human growth hormone market size was estimated at USD 5.47 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.3% from 2023 to 2030. The market is experiencing expansion due to factors, such as the growing awareness about growth hormones and its increased utilization for the treatment of hormonal imbalance disorders. Moreover, leading pharmaceutical and biopharmaceutical companies are undertaking significant R&D efforts to bring novel hormone therapies to the market. These therapies aim to provide long-term action and enhanced safety profiles, further driving the development of the market on a global scale. The increasing incidence of growth hormone deficiencies resulting from congenital conditions, genetic disorders, brain injuries, and specific medical therapies has led to a higher demand for hormone treatments.

According to the NCBI, pediatric growth hormone deficiency is diagnosed in approximately 1 in every 3,500-4,000 children in the UK. In addition, the growth hormone industry is experiencing an increase due to ongoing research and development activities in this field. For example, in February 2022, OPKO and Pfizer obtained marketing approval from the European Union for its Once-Weekly NGENLA (somatrogon) Injection, which is used in the treatment of pediatric growth hormone deficiency. Furthermore, the early detection of endocrine illnesses including Hashimoto thyroiditis, Graves’ disease, Cushing's disease, Addison's disease, hyperthyroidism/hypothyroidism, and prolactinoma among others, plays a crucial role in improving treatment outcomes and preventing severe complications.

Governments and international organizations have initiated various campaigns and programs to promote early diagnosis. For instance, in 2019, the International Coalition of Organizations Supporting Endocrine Patients, a U.S.-based organization, introduced International Children's Growth Awareness Day to raise alertness about the importance of early detection in identifying endocrine disorders. The market expansion is expected to be influenced by the COVID-19 pandemic. According to a Frontiers article, individuals with low production of growth hormone are considered at risk for COVID-19, emphasizing the importance of preventive measures in this population.

Individuals with Turner syndrome and Prader-Willi disorder are advised to take extra precautions due to their heightened susceptibility to severe illness caused by the COVID-19 virus. Growth hormone deficiency happens when the pituitary gland fails to produce an adequate amount of growth hormone. Such a hormone deficiency is usually managed through subcutaneous injections of human growth hormone (HGH). Genetic conditions, such as Turner syndrome and Prader-Willi condition, can also lead to deficiency, which has resulted in delayed puberty and shorter stature compared to the general population.

Furthermore, industry participants are focusing their investments on the delivery and monitoring aspects of HGH therapy to enhance effectiveness and scalability for future advancements. For instance, in October 2022, Merck KGaA partnered with Biocorp to develop and supply a customized version of the Mallya device for monitoring the treatment of HGH disorders. Similarly, in April 2021, the company chose PRA Health Sciences' remote patient monitoring platform to enhance the product experience. These collaborations and initiatives reflect the commitment of market players to optimize the delivery and monitoring of hormone therapy, thereby improving patient outcomes and treatment management.

Product Insights

Based on product, the market is divided into long-acting and others. In 2022, the other segments accounted for the largest market share of 95.5%. This segment is projected to maintain a steady progress rate throughout the forecast period. Other segments within the market include short-acting and intermediate-acting growth hormones. The segment is anticipated to witness significant traction over the forecast period owing to an increase in the incidence of insufficiency coupled with the presence of various products, such as Genotropin (Pfizer Inc.), Humatrope (Eli Lilly & Co.), Saizen (Merck & Co. Inc.), and Norditropin (Novo Nordisk A/S), among others.

In addition, the recent product launches and high adoption of short-acting preparations owing to their lower incidence of side effects is another factor contributing to segment expansion. The long-acting segment is expected to register the fastest growth rate during the forecast period. Advantages, such as reduced frequency of administration, improved patient compliance, and convenience, are augmenting the segment growth. Similarly, the robust investigational pipeline and recent product launches are fueling the segment growth. For instance, in January 2022, Ascendis Pharma A/S announced the EC approval for marketing authorization of SKYTROFA for the treatment of children and adolescents aged 3 to 18 years with growth failure.

Application Insights

The growth hormone deficiency segment accounted for the largest revenue share of around 48.7% in 2022 and is anticipated to grow at the fastest CAGR during the forecast period. Increasing awareness about the importance of early diagnosis and treatment of hormone deficiency, along with the endeavors of biopharmaceutical companies to introduce innovative therapies, are driving the adoption of this segment. For instance, in May 2023, Novo Nordisk declared that the Committee for Medicinal Products for Human Use of the European Medicines Agency had released a favorable statement recommending the use of once-weekly Sogroya (somapacitan). The recommendation is for the treatment of growth hormone deficiency in children aged three years and above, as well as adolescents with development failure.

This positive development highlights the potential of Sogroya as a replacement therapy for endogenous growth hormone in these patient populations. The high prevalence of Turner syndrome, increased research in the field of rare genetic conditions, and various initiatives by public and private organizations to raise awareness about the condition are key factors driving the market share of the Turner syndrome segment. Organizations, such as the Turner Syndrome Foundation, Turner Syndrome Society of the United States, and Turner Syndrome Support Society, are playing a crucial role in spreading awareness and promoting the diagnosis of Turner syndrome.

Distribution Channel Insights

The hospital pharmacy segment dominated the market with the largest revenue share of 36.4% in 2022. The increasing prevalence of the disease, higher frequency of hospital visits, and favorable reimbursement policies are driving the adoption of this segment. Moreover, patients are showing a preference for recombinant and artificial HGH, which is readily available in hospital pharmacies. These factors are contributing to the growth and application of this segment. The online pharmacy segment is expected to experience rapid growth in the coming years.

This increase can be attributed to the widespread presence of online pharmacies in lucrative regions, such as Europe and North America, increased patient awareness, and the growing popularity of e-commerce & telehealth services. The online pharmacy segment benefits from factors, such as flexibility, convenience, and attractive discounts on medicines, which further contribute to its growth. The retail pharmacy segment held the second-highest revenue share in 2022, primarily due to the availability of major pharmacy chains, such as Walgreens, Walmart, and CVS Caremark. These retail pharmacies play a significant role in providing access to a wide range of medications and healthcare products to consumers, contributing to the segment's growth.

Regional Insights

North America led the market in 2022 with a share of 42.27% of the overall revenue due to the high healthcare awareness among people, significant government initiatives, and favorable reimbursement policies in the region. Increasing R&D activities in the region, adequate research funding, and the presence of organizations that facilitate awareness & treatment rates in the region are anticipated to boost the regional market expansion. Furthermore, the strong presence of leading participants, such as Pfizer Inc. and Lilly, is expected to support the region’s growth. Europe holds the second-largest market share due to the factors, such as the increasing burden of growth hormone deficiencies, availability of artificial growth hormones, and extensive R&D activities in the region.

The prevalence of growth hormone deficiency is on the rise in Europe due to factors, such as stress, inadequate sleep, and low glucose levels among individuals. For instance, in 2021, the European Medicines Agency reported that growth hormone deficiency impacted around 4.7 out of 10,000 people in the European Union. Germany holds the largest share in the Europe regional market, while France is projected to experience the fastest CAGR from 2023 to 2030. Asia Pacific is anticipated to have a lucrative growth rate during the forecast period due to the high disease burden of rare genetic conditions, unmet medical needs, and increasing demand for innovative therapeutics. Furthermore, the region benefits from the rising investments made by leading market participants, attracted by the flourishing pharmaceutical sector in APAC.

Key Companies & Market Share Insights

Key players are adopting strategies, such as new product development, merger & acquisition, and partnership, to increase their market share. Companies, such as Pfizer Inc., Novartis AG, and Merck & Co., Inc., are actively involved in the development of HGH. For instance, in January 2022, Ascendis Pharma A/S received approval from the European Commission for its product TransCon hGH. TransCon hGH is indicated for the treatment of pediatric patients diagnosed with growth hormone deficiency. It contains somatropin, a synthetic form of HGH. The approval from the European Commission signifies that TransCon hGH has met the necessary regulatory requirements and can be marketed & used for the intended indication in the European Union. Some of the key players in the global human growth hormone market include:

• Novo Nordisk A/S

• Eli Lilly and Company

• Pfizer, Inc.

• Sandoz International GmbH (Novartis AG)

• Genentech, Inc. (Roche)

• Merck KGaA

• Ferring Pharmaceuticals

• Ipsen

• Teva Pharmaceutical Industries, Ltd.

Human Growth Hormone Market Report Scope

Global Human Growth Hormone Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global human growth hormone market report on the basis of product, application, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Long Acting

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Growth Hormone (GH) Deficiency

    • Adult GH Deficiency

    • Pediatric GH Deficiency

  • Turner Syndrome

  • Idiopathic Short Stature

  • Prader-Willi Syndrome

  • Small for Gestational Age

  • Other

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

  • Specialty Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait